[go: up one dir, main page]

DK1456238T3 - Produktion af F(ab')2-fragmenter i pattedyrceller - Google Patents

Produktion af F(ab')2-fragmenter i pattedyrceller

Info

Publication number
DK1456238T3
DK1456238T3 DK02789019T DK02789019T DK1456238T3 DK 1456238 T3 DK1456238 T3 DK 1456238T3 DK 02789019 T DK02789019 T DK 02789019T DK 02789019 T DK02789019 T DK 02789019T DK 1456238 T3 DK1456238 T3 DK 1456238T3
Authority
DK
Denmark
Prior art keywords
fragments
production
mammalian cells
antibody fragments
bivalent
Prior art date
Application number
DK02789019T
Other languages
English (en)
Inventor
Abraham Bout
David Halford Ashton Jones
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of DK1456238T3 publication Critical patent/DK1456238T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624Disulfide-stabilized antibody (dsFv)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/108Plasmid DNA episomal vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK02789019T 2001-12-17 2002-12-17 Produktion af F(ab')2-fragmenter i pattedyrceller DK1456238T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL0100917 2001-12-17
PCT/NL2002/000841 WO2003051927A2 (en) 2001-12-17 2002-12-17 Production of f(ab')2 fragments in mammalian cells

Publications (1)

Publication Number Publication Date
DK1456238T3 true DK1456238T3 (da) 2008-08-18

Family

ID=19760784

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02789019T DK1456238T3 (da) 2001-12-17 2002-12-17 Produktion af F(ab')2-fragmenter i pattedyrceller

Country Status (11)

Country Link
US (2) US20050048038A1 (da)
EP (1) EP1456238B1 (da)
AT (1) ATE397019T1 (da)
AU (1) AU2002353662B2 (da)
CA (1) CA2470579C (da)
DE (1) DE60226896D1 (da)
DK (1) DK1456238T3 (da)
ES (1) ES2307807T3 (da)
NZ (1) NZ533332A (da)
SI (1) SI1456238T1 (da)
WO (1) WO2003051927A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
DE60224843T2 (de) 2001-12-07 2009-01-08 Crucell Holland B.V. Herstellung von viren, virusisolaten, und impfstoffen
US20050048038A1 (en) 2001-12-17 2005-03-03 Jones David Halford Ashton Efficient production of f(ab')2 fragments in mammalian cells
KR101183770B1 (ko) 2003-05-09 2012-09-17 크루셀 홀란드 비.브이. E1-불멸화된 세포의 배양물 및 이로부터 생성 수율을 증가시키기 위한 동일물의 배양 방법
MA49426B1 (fr) 2017-10-02 2022-09-30 Laboratorios Silanes S A De C V Processus à haut rendement pour la production d’antivenins à partir de fragments d’anticorps f(ab') 2
WO2023205656A2 (en) * 2022-04-18 2023-10-26 John Paul Ii Medical Research Institute Immortalized cells for production of bioproducts, methods of producing bioproducts with an immortalized cell, and methods of making immortalized cells for production of bioproducts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US7018809B1 (en) * 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
KR100449181B1 (ko) 1995-06-15 2005-01-24 크루셀 홀란드 비.브이. 유전자요법에사용할수있는사람의재조합아데노바이러스패키징시스템
PT1161548E (pt) * 1999-04-15 2005-06-30 Crucell Holland Bv Producao de proteinas recombinantes numa celula humana utilizando sequencias codificando a proteina e1 de adenovirus
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
EP1130099A1 (en) * 2000-02-25 2001-09-05 Crucell Holland B.V. Activated vitronectin as a marker of angiogenesis detected with phage antibodies
US20050048038A1 (en) 2001-12-17 2005-03-03 Jones David Halford Ashton Efficient production of f(ab')2 fragments in mammalian cells

Also Published As

Publication number Publication date
EP1456238B1 (en) 2008-05-28
WO2003051927A3 (en) 2003-11-20
CA2470579C (en) 2012-03-06
EP1456238A2 (en) 2004-09-15
CA2470579A1 (en) 2003-06-26
SI1456238T1 (sl) 2008-08-31
US20080166767A1 (en) 2008-07-10
DE60226896D1 (de) 2008-07-10
US20050048038A1 (en) 2005-03-03
US7537916B2 (en) 2009-05-26
WO2003051927A2 (en) 2003-06-26
ES2307807T3 (es) 2008-12-01
AU2002353662A1 (en) 2003-06-30
ATE397019T1 (de) 2008-06-15
NZ533332A (en) 2005-07-29
AU2002353662B2 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
DK1456238T3 (da) Produktion af F(ab')2-fragmenter i pattedyrceller
DE60238308D1 (de) Schnellproduktion monoklonaler antikörper
TR200001946T2 (tr) Aşı
DK1650307T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner ved anvendelse af apoptoseinhibitorer
AU2002364935A1 (en) Enhancement of immune responses by 4-1bb-binding agents
DE60236016D1 (de) Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
ATA165999A (de) Medium zur protein- und serumfreien kultivierung von zellen
DE60037450D1 (de) Funf-helix protein
BR0015224A (pt) Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado
NZ592159A (en) Means and methods for influencing the stability of antibody producing cells
NO20061470L (no) Fremgangsmate for fremstilling av gamma-karboksylerte proteiner
SI1644484T1 (sl) Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah
DE60332966D1 (de) Kollektoren in zwei hemispheren
PT1451302E (pt) Folhas reconstituídas in vitro de epitélio corneal humano e método de produção das mesmas
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
PT1200561E (pt) Clone celular recombinante estavel, sua producao e utilizacao
HK1063334A1 (en) Compositions and methods useful for hcv infection
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
MX2023011316A (es) Construcciones de anticuerpos modificados con cisteina, conjugados y metodos de uso.
GB2351296A (en) Keratinocyte stem cells
SE0002835D0 (sv) Method and kit for production of monoclonal antibodies
TR200100013T2 (tr) N-tert-butilhidroksilaminin yeni tuzları.
GB2379446A (en) Cells,culture methods and their uses